Lingxi Jiang

1.9k total citations
53 papers, 792 citations indexed

About

Lingxi Jiang is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Lingxi Jiang has authored 53 papers receiving a total of 792 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 16 papers in Oncology and 10 papers in Epidemiology. Recurrent topics in Lingxi Jiang's work include Ophthalmology and Visual Impairment Studies (8 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Retinal Diseases and Treatments (5 papers). Lingxi Jiang is often cited by papers focused on Ophthalmology and Visual Impairment Studies (8 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Retinal Diseases and Treatments (5 papers). Lingxi Jiang collaborates with scholars based in China, Hong Kong and Australia. Lingxi Jiang's co-authors include Chunbao Xie, Yi Shi, Bo Gong, Zhenglin Yang, Xingxiang Yang, He Lin, Hua Yu, Hong Pu, Guo Si and Bo Long and has published in prestigious journals such as Advanced Materials, PLoS ONE and Cancer Research.

In The Last Decade

Lingxi Jiang

46 papers receiving 782 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lingxi Jiang China 15 296 194 151 123 102 53 792
Queenie Fernandes Qatar 14 194 0.7× 200 1.0× 192 1.3× 79 0.6× 109 1.1× 26 753
Aleksander Sochanik Poland 17 380 1.3× 72 0.4× 162 1.1× 111 0.9× 58 0.6× 52 829
Kai-Wen Cheng Taiwan 17 400 1.4× 204 1.1× 129 0.9× 53 0.4× 48 0.5× 31 761
Jia You China 17 238 0.8× 46 0.2× 139 0.9× 133 1.1× 97 1.0× 52 861
Zhaoyang Chen China 19 456 1.5× 120 0.6× 34 0.2× 97 0.8× 138 1.4× 54 1.1k
Xiaohua Chen China 18 316 1.1× 161 0.8× 74 0.5× 39 0.3× 108 1.1× 73 1.0k
Sachin Mittal India 15 243 0.8× 58 0.3× 128 0.8× 88 0.7× 34 0.3× 61 734
Yongshu Li China 14 362 1.2× 55 0.3× 138 0.9× 123 1.0× 54 0.5× 52 664
Zohreh Jahanafrooz Iran 13 329 1.1× 158 0.8× 95 0.6× 47 0.4× 79 0.8× 25 712
Sina Taefehshokr Iran 17 324 1.1× 118 0.6× 195 1.3× 63 0.5× 160 1.6× 23 778

Countries citing papers authored by Lingxi Jiang

Since Specialization
Citations

This map shows the geographic impact of Lingxi Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingxi Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingxi Jiang more than expected).

Fields of papers citing papers by Lingxi Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lingxi Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingxi Jiang. The network helps show where Lingxi Jiang may publish in the future.

Co-authorship network of co-authors of Lingxi Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Lingxi Jiang. A scholar is included among the top collaborators of Lingxi Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lingxi Jiang. Lingxi Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Ting, Jiejie Qin, Yizhi Cao, et al.. (2025). CEMIP2 sensitizes PDAC to chemotherapy through extracellular matrix remodeling by hyaluronan degradation. Cancer Letters. 630. 217898–217898. 1 indexed citations
2.
Qin, Xianyan, Yang‐Bao Miao, Qin Wang, et al.. (2025). Harnessing engineered adaptive nanoparticles to modulate macrophages for treating corneal alkali burns. Journal of Controlled Release. 387. 114253–114253.
3.
Luo, Jiaxin, Zhenyu Ding, Dongjie Chen, et al.. (2025). TFAP2A enhances tumor stemness and promotes metastasis in pancreatic ductal adenocarcinoma. iScience. 28(8). 113060–113060.
5.
Jiang, Lingxi, Danni Zheng, Juan Ni, et al.. (2024). P2.10B.04 Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: A Multicenter Real-World Study. Journal of Thoracic Oncology. 19(10). S248–S249. 1 indexed citations
6.
Jiang, Lingxi, Tingting Wang, Chunbao Xie, et al.. (2024). Uncovering a novel SERPING1 pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema. Orphanet Journal of Rare Diseases. 19(1). 341–341. 1 indexed citations
7.
Jiang, Lingxi, Lulin Huang, Chao Dai, et al.. (2024). Genome‐Wide Association Analysis Identifies LILRB2 Gene for Pathological Myopia. Advanced Science. 11(40). e2308968–e2308968. 5 indexed citations
8.
Dai, Chao, Wei Yao, Chunbao Xie, et al.. (2023). A Novel Pair of Compound Heterozygous Mutation of EYS in a Han Chinese Family with Retinitis Pigmentosa. Genetic Testing and Molecular Biomarkers. 27(8). 258–266.
10.
Shi, Minmin, Zhichong Wu, Meilin Xue, et al.. (2023). LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability. Journal of Translational Medicine. 21(1). 838–838. 10 indexed citations
11.
Jiang, Yongsheng, Lijie Han, Jian Yang, et al.. (2023). Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal adenocarcinoma. Cancer Immunology Immunotherapy. 72(8). 2701–2716. 5 indexed citations
13.
Jiang, Lingxi, Xia Wang, Fangfang Ma, et al.. (2022). PITX2C increases the stemness features of hepatocellular carcinoma cells by up-regulating key developmental factors in liver progenitor. Journal of Experimental & Clinical Cancer Research. 41(1). 211–211. 10 indexed citations
14.
Zhu, Youwei, Meilin Xue, Yongsheng Jiang, et al.. (2020). Mycophenolate mofetil preconditioning protects mouse liver against ischemia/reperfusion injury in wild type and toll-like receptor 4 knockout mice. Transplant Immunology. 65. 101357–101357. 2 indexed citations
15.
Tang, Xuming, Tingting Cao, Yun Zhu, et al.. (2020). PIM2 promotes hepatocellular carcinoma tumorigenesis and progression through activating NF-κB signaling pathway. Cell Death and Disease. 11(7). 510–510. 24 indexed citations
16.
Shi, Minmin, Kexian Li, Yang Ma, et al.. (2020). Development and validation of a cancer stem cell-related signature for prognostic prediction in pancreatic ductal adenocarcinoma. Journal of Translational Medicine. 18(1). 360–360. 25 indexed citations
17.
Tang, Hong, Lingxi Jiang, Raymond Liu, et al.. (2019). Loss of cell adhesion molecule L1 like promotes tumor growth and metastasis in esophageal squamous cell carcinoma. Oncogene. 38(17). 3119–3133. 25 indexed citations
18.
Jiang, Lingxi, Tingting Wang, Rui Zheng, et al.. (2019). Evaluation of FGF10 as a candidate gene for high myopia in a Han Chinese population. Eye and Vision. 6(1). 33–33. 6 indexed citations
19.
Wu, Haiyan, Lingxi Jiang, Rui Zheng, et al.. (2018). Genetic Association Study Between the COL11A1 and COL18A1 Genes and High Myopia in a Han Chinese Population. Genetic Testing and Molecular Biomarkers. 22(6). 359–365. 2 indexed citations
20.
Ye, Zimeng, Ping Shuai, Lingxi Jiang, et al.. (2016). Associations of 6p21.3 Region with Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Scientific Reports. 6(1). 20914–20914. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026